A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)

Recruiting

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(7 sites)

United States

Arkansas Children's Hospital, Little Rock, Arkansas

Stanford University, Palo Alto, California

University of California, Davis, Sacramento, California

Washington University in St. Louis, St Louis, Missouri

Nationwide Children's Hospital, Columbus, Ohio

Neurology Rare Disease Center, Flower Mound, Texas

Children's Hospital of The King's Daughters, Norfolk, Virginia